Status:

COMPLETED

Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma

Lead Sponsor:

Centre Leon Berard

Collaborating Sponsors:

Amgen

Conditions:

Lymphoma

Myeloma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the efficacy and tolerance of a single administration of Pegfilgrastim in patients with lymphoma or myeloma receiving high-dose chemotherapy and autologous per...

Detailed Description

High-dose chemotherapy with autologous peripheral stem cell (PSC) transplantation is a standard consolidation treatment for the initial management of patients with myeloma treated with high-dose Melph...

Eligibility Criteria

Inclusion

  • Male or female patients aged ≥ 18 years
  • Patients with histologically confirmed lymphoma or myeloma
  • Treatment with high-dose chemotherapy before inclusion
  • Intensification with high dose Melphalan for patients with myeloma
  • Whatever the conditioning regimen, except TBI for patients with 1st relapse of Hodgkin's lymphoma or with MNHL NB: Patients having received two intensification courses are eligible if there has been more than 100 days between courses.
  • Autologous PSC transplantation at the time of inclusion
  • Reinjection of ≥ 2.106 CD34/kg
  • Patients hospitalized in the investigator center throughout the procedure until recovery from aplasia (PNN \> 0.5 G/L)
  • Mandatory affiliation with a health insurance system
  • Patients able to understand, read and write French
  • Signed, written informed consent

Exclusion

  • TBI during conditioning
  • Severe intolerance to the growth factor under study, or hypersensitivity to one of their components
  • Immunosuppressive syndrome
  • Pregnant or lactating women
  • Difficult follow-up
  • Documented history of cognitive or psychiatric disorders
  • Participation or consideration of participation in another biomedical study during the follow-up period of the present trial.

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2010

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00794261

Start Date

September 1 2008

End Date

June 1 2010

Last Update

July 8 2010

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

CHU Angers

Angers, France, 49000

2

CHU Brest

Brest, France, 29609

3

Centre Leon Berard

Lyon, France, 69008

4

Hopital Edouard Herriot

Lyon, France, 69008